| Title |
Efficacy of levetiracetam for neonatal seizures in preterm infants
|
|---|---|
| Published in |
BMC Pediatrics, April 2018
|
| DOI | 10.1186/s12887-018-1103-1 |
| Pubmed ID | |
| Authors |
Ji Yoon Han, Chung Joon Moon, Young Ah Youn, In Kyung Sung, In Goo Lee |
| Abstract |
Neonatal seizures remain a significant clinical problem, and therapeutic options are still not diverse with limited efficacy. Levetiracetam (LEV) is a relatively new and wide spectrum anti-seizure medication with favorable pharmacokinetics and safety profile. In the recent decades, LEV has been increasingly used for the treatment of neonatal seizures. The aim of this study was to describe the experience of using LEV as the first line anti-seizure medication for preterm infants. A retrospective analysis of 37 preterm infants who were treated with LEV as the first-line anti-seizure medication was performed. Mean gestational age of the 37 preterm infants was 31.5 ± 1.9 weeks (range, 26 to 36+ 6 weeks). Twenty-one infants (57%) were seizure-free while given LEV at the end of the first week, and no additional anti-seizure medication was required. Loading doses of LEV ranged from 40 to 60 mg/kg (mean 56 mg/kg) and the maintenance dose ranged from 20 to 30 mg/kg (mean 23 mg/kg). No adverse effect was observed. Levetiracetam can be a good and safe choice for treatment of neonatal seizures in preterm infants. Prospective double blind controlled studies are needed in the future. |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 9% |
| Student > Master | 6 | 9% |
| Student > Postgraduate | 5 | 8% |
| Student > Bachelor | 4 | 6% |
| Researcher | 4 | 6% |
| Other | 14 | 22% |
| Unknown | 26 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 15% |
| Neuroscience | 4 | 6% |
| Agricultural and Biological Sciences | 1 | 2% |
| Veterinary Science and Veterinary Medicine | 1 | 2% |
| Other | 2 | 3% |
| Unknown | 26 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2018.
All research outputs
#5,815,414
of 23,041,514 outputs
Outputs from BMC Pediatrics
#920
of 3,040 outputs
Outputs of similar age
#101,484
of 329,244 outputs
Outputs of similar age from BMC Pediatrics
#41
of 71 outputs
Altmetric has tracked 23,041,514 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 3,040 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,244 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.